INTRODUCTION: Izazomib is a proteosome inhibitor indicated for use in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.
Structural formula:
Properties
Summary
Isazomib is an orally administered proteasome inhibitor with high selectivity. Isazomib is used in conjunction with lenalidomide and dexamethasone to treat multiple myeloma that has received at least first-line treatment in the past.
CRO
